Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality

17 Dec 2018

Abstract excerpt

Although genomic analysis have recently discovered the malignant subtype of human pancreatic ductal adenocarcinoma (PDAC) characterized by frequent mutations of histone demethylase KDM6A, the biological and molecular roles still remain obscure. We herein elucidated the clinical and biological impacts of KDM6A deficiency on human PDAC and identified the therapeutic potential by pathological and molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Pancreatic and Hepatic Oncology Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30556125
DOI: 10.1002/ijc.32072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethalityPMID 30556125Read ↗

Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPαSemantic proximity Read ↗

HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.Semantic proximity Read ↗

The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programsSemantic proximity Read ↗

Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for TherapySemantic proximity Read ↗

Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia–mesenchymal transition during pancreatic carcinogenesisSemantic proximity Read ↗

Prognostic Value and Molecular Mechanisms of Proteasome 26S Subunit, Non-ATPase Family Genes for Pancreatic Ductal Adenocarcinoma Patients after PancreaticoduodenectomySemantic proximity Read ↗

Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasetsSemantic proximity Read ↗

Epigenetic Landscape of DNA Methylation in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancerSemantic proximity Read ↗

Genetic alterations and functional networks of m6A RNA methylation regulators in pancreatic cancer based on data miningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.